Persistent Gingival Bleeding After Scaling: A Diagnostic Clue to von Willebrand Disease Authors: Huihui Zhang, Nan Qiu, Zhengguo Cao, Shuhuan Shang Published: 2026 ABSTRACT ABSTRACTVon Willebrand disease (VWD) is not a rare inherited bleeding disorder. However, it is frequently underdiagnosed because early mucocutaneous bleeding manifestations are often attributed to local factors such as inflammation or anatomical abnormalities, leading to delayed recognition of the underlying systemic disease. A 31‐year‐old Han Chinese female presented with persistent gingival bleeding after routine dental scaling. Her medical history was notable for lifelong recurrent epistaxis and severe intraoperative bleeding during a previous cesarean section, both of which had been attributed to local causes. Her father also had a history of childhood epistaxis. Considering the suggestive personal and family bleeding history, the periodontist suspected an underlying systemic bleeding disorder and referred her to a hematologist. Further laboratory and genetic testing confirmed a diagnosis of type 2M/2A VWD, a rare and recently defined subtype. This case highlights two important clinical messages. First, clinical practitioners, including dentists, can serve as key first responders in identifying systemic disorders by carefully evaluating bleeding and family histories rather than focusing solely on local oral conditions. Second, a comprehensive, patient‐centered diagnostic approach is essential to avoid delayed diagnosis of inherited bleeding disorders such as VWD. This case report emphasizes the important role of non‐hematology clinicians in the early diagnosis of rare VWD subtypes.Keywords: case report, gingival bleeding, inherited bleeding disorder, periodontology, von Willebrand disease Abbreviations activated partial thromboplastin time Bleeding Assessment Tool complete blood count desmopressin factor FVIII FVIII coagulant activity gingival recession International Society for Thrombosis and Hemostasis oral hygiene index‐simplified probing depth prothrombin time ristocetin‐induced platelet agglutination sulcus bleeding index tooth mobility thrombin time von Willebrand disease von Willebrand factor antigen CB/VWF:Ag ratio of VWF collagen‐binding activity to VWF antigen VWF FVIII binding Introduction Von Willebrand disease (VWD), first described in 1926, is the most common inherited bleeding disorder. However, it remains underdiagnosed and is often perceived as “rare,” primarily due to limited awareness among non‐hematology clinicians—particularly dental practitioners [1, 2, 3, 4, 5, 6]. The primary pathogenic mechanism of von Willebrand disease (VWD) involves genetic mutations of von Willebrand factor (VWF), which is a multimeric plasma glycoprotein critical for platelet adhesion, aggregation, and circulating factor VIII stabilization, leading to reduced plasma VWF levels or abnormal VWF function. VWD is classified into three main types based on pathogenic mechanisms and clinical manifestations, with significant individual variability in bleeding severity. Patients with type 1 VWD may be asymptomatic, while most type 2 patients present with moderate bleeding—often more severe in females—and type 3 VWD is associated with the most severe bleeding. Types 1 and 2 account for the majority of VWD cases [7, 8, 9, 10]. Among type 2 subtypes, type 2A and 2M are particularly easily overlooked due to their relatively mild and atypical bleeding phenotypes, which do not present with severe spontaneous hemorrhage and are often only triggered by invasive minor procedures, including routine dental treatment [11]. Although VWD typically presents early in life, with skin and mucous membrane bleeding as its primary manifestation [7, 12, 13], clinicians often attribute such bleeding to local factors, such as anatomical anomalies or localized inflammation. This diagnostic bias is especially prominent in dental clinical settings, where postoperative gingival bleeding is routinely regarded as a trivial and self‐limiting complication of scaling and root planing, rather than a potential warning sign of underlying systemic bleeding diseases. This common oversight leads to the neglect of potential underlying systemic bleeding disorders, resulting in delayed or missed diagnoses for many VWD patients. In this case report, we present a unique diagnostic pathway involving a 31‐year‐old woman who developed persistent gingival bleeding after routine ultrasonic supragingival scaling—a common dental procedure. Comprehensive laboratory evaluation ultimately led to the diagnosis of a rare VWD subtype (type 2M/2A). Given the paucity of clinical literature focusing on atypical mild VWD diagnosed incidentally through routine dental scaling, this case provides valuable real‐world clinical evidence for the early identification of easily neglected VWD subtypes. A concise review of relevant literature is integrated to highlight the educational and clinical implications of this case, with the goal of enhancing clinician awareness of VWD and facilitating earlier detection and timely diagnosis in similar clinical scenarios—especially in dental settings. Case History/Examination A 31‐year‐old Han Chinese female, a college professional teacher, presented to the Department of Periodontology for routine dental cleaning due to poor oral hygiene. During the initial routine interview, she denied a history of systemic disease, trauma, drug allergy, or spontaneous gingival bleeding. She also denied any family history of bleeding disorders. On physical examination, the patient was alert, well‐developed and well‐nourished, with a ruddy complexion and pink lower palpebral conjunctiva without evidence of anemic pallor. A band‐aid was noted on the right temporal area; upon further inquiry, the patient reported that a nevus had been excised at another hospital approximately 3 weeks prior, with no abnormal postoperative bleeding. Periodontal examination revealed an Oral Hygiene Index‐Simplified (OHI‐S) score of 3, with a small amount of supragingival calculus and obvious banded subgingival calculus deposits. The gingiva was dark red, slightly edematous, and soft, with a Sulcus Bleeding Index (SBI) of 2–4, probing depth (PD) of 2–5 mm, gingival recession (GR) of 0–2 mm, and no tooth mobility (TM = 0) or tooth loss. Orthopantomogram findings are shown in Figure 1. A diagnosis of localized periodontitis (Stage II, Grade A) in stable condition was established for the patient, in accordance with the 2017 World Workshop classification system for periodontal and peri‐implant diseases and conditions [14]. Baseline laboratory examination results are presented in Table 1. Orthopantomogram of the patient at initial presentation. The panoramic radiograph shows localized horizontal bone loss in the anterior and bicuspid area of the mandible, with no evidence of other significant bone defects or periapical pathology. TABLE 1Laboratory tests of the patient at the initial visit to the Department of Periodontology.IndexDataReference rangeWhite blood cells (109/L)6.223.5–9.5Red blood cells (1012/L)4.303.8–5.1Hemoglobin (g/L)120115–150Hematocrit (%)3635–45Mean corpuscular volume (fL)83.782–100Mean corpuscular hemoglobin (pg)27.927–34Mean corpuscular hemoglobin concentration (g/L)333316–354Platelets (109/L)268100–350Mean platelet volume (fL)9.49.0–13.0Basophil cell (109/L)0.130–0.06Basophil cell (%)2.100–1Prothrombin time (PT) (s)10.69–14International normalized ratio (INR)0.960.8–1.3Activated partial thromboplastin time (APTT) (s)33.820–38Thrombin time (TT) (s)17.213–20 Laboratory tests of the patient at the initial visit to the Department of Periodontology. Differential Diagnosis, Investigations and Treatment No obvious contraindications to scaling were identified, and the patient was referred to a dental hygienist for full‐mouth ultrasonic supragingival scaling. During the procedure, significant gingival bleeding was noted, so the patient was monitored in the clinic for 30 min to assess spontaneous hemostasis. After 30 min, bleeding persisted, with visible oozing from the lingual gingival papillae of teeth 43, 44, and 34. Initial hemostatic measures included local irrigation with iodine‐oxygen solution and compression of bleeding sites with iodine‐phenol‐soaked cotton balls. Subsequent application of a clove oil‐free periodontal dressing (Bonagao, Bonanga Technology Co. Ltd.) did not significantly reduce bleeding. Interrupted suturing of the lingual gingival papillae of teeth 43, 44, and 34 partially controlled bleeding, which was further relieved by local submucosal injection of Bothrops Atrox thrombin (Baquting, Shandong Penglai Nuokang Pharmaceutical Co. Ltd.). Finally, a collagen membrane (Bonamo, Bonanga Technology Co. Ltd.) was placed in the interdental spaces of the bleeding sites, with lateral mattress suturing to achieve hemostasis. After 30 min of observation with no further obvious bleeding, the patient was discharged with advice to undergo hematological evaluation as soon as possible. During hemostatic treatment, further questioning revealed additional relevant medical history: lifelong unexplained skin bruising with ecchymoses > 1 cm in diameter; frequent epistaxis lasting > 30 min in childhood (decreasing to ≤ 1 episode/year in adulthood), which her otolaryngologist attributed to thin‐walled blood vessels in Kiesselbach's area. She had heavy menstrual bleeding during middle school (7‐day cycles, with heavy bleeding and blood clots requiring pad changes every 45 min during the first 3 days and sanitary pants changes on the first night); since her PhD studies, menstrual flow has decreased to 5‐day cycles with heavy bleeding only on day 1. Five years prior, she had experienced prolonged bleeding for nearly 1 day after dental scaling at another clinic, which resolved spontaneously without medical intervention. In July 2022, significant placental surface oozing occurred during a cesarean section, which required ligation of the right ascending branch of the uterine artery for hemostasis. Her obstetrician attributed this to local endometrial thinning or inflammation, with normal preoperative routine hematological tests. The patient reported that her father had a history of childhood epistaxis (mild, easily controlled) with no persistent bleeding after nevus excision or dental implantation, and that he had normal previous routine hematological tests. On the morning after scaling, the patient reported mild oral bleeding after brushing via WeChat and was advised to return to the hospital. On reexamination, only slight bleeding was noted in the right bicuspid area. Absorbable hemostatic satin (S‐100 Absorbable Hemostat, Beijing Taikesiman Technology Development Co. Ltd.) was placed in the local interdental spaces and covered with industrial zinc oxide paste impregnated with Yunnan Baiyao (Yunnan Baiyao Group CO. Ltd), a traditional Chinese hemostatic agent. No bleeding was observed after 30 min of observation, and the patient was discharged. During follow‐up, the patient reported no further oral bleeding and provided hematological examination records and results in the Department of Hematology (detailed in Tables 2, 3, 4, 5, 6). Genetic testing for von Willebrand factor (VWF) antigen revealed a heterozygous missense mutation (c.4120C > T), resulting in an amino acid change from arginine to cysteine at position 1374 of the VWF protein. This case was registered in the Human Gene Mutation Database, Cardiff University, UK (ID: CM951304). Her only child underwent VWD screening, with abnormal results shown in Table 7. TABLE 2Results of routine hematological tests and coagulation time examinations on the second day after scaling.IndexDataReference rangeWhite blood cells (109/L)6.033.5–9.5Red blood cells (1012/L)4.493.80–5.10Hemoglobin (g/L)125.0115.0–150.0Hematocrit (%)38.035.0–45.0Mean corpuscular volume (fL)84.682.0–100.0Mean corpuscular hemoglobin (pg)27.827.0–34.0Mean corpuscular hemoglobin concentration (g/L)329316–354Platelets (109/L)301.0125.0–350.0Mean platelet volume (fL)10.19.0–13.8Basophil cell (109/L)0.180.00–0.10Basophil cell (%)3.00.0–1.0Prothrombin time (s)12.19.4–12.5Prothrombin activity (%)89.080–130International normalized ratio1.110.84–1.15Fibrinogen (g/L)3.361.9–4.0Activated partial thromboplastin time (s)42.725.0–38.0Thrombin time (s)13.211.0–17.0D‐D dimer quantification (μg/mL FEU)< 0.22< 0.5Total immunoglobulin E (IU/mL)7.18≦ 100 Results of routine hematological tests and coagulation time examinations on the second day after scaling. TABLE 3Results of the platelet aggregation test of the patient on the second day after scaling.IndexDataReference rangeMaximum aggregation rate (6 μM ADP) (%)77.350.0–100.0ADP‐induced aggregation curveMonomial aggregationMonomial aggregationMaximum aggregation rate (0.3 g/L Arachidonic acid) (%)94.755.0–100.0Maximum aggregation rate (5 mg/L Collagen) (%)89.055.0–100.0Maximum aggregation rate (180 μM Epinephrine) (%)97.755.0–100.0 Results of the platelet aggregation test of the patient on the second day after scaling. TABLE 4Results of the thromboelastogram test a of the patient on the second day after scaling.IndexDataReference range R (min)5.24–9 K (min)1.21–3ANGLE76.958–78MA (mm)66.650–70EPL (%)0.00–15CI2.4−3 to 3LY30 (%)0.00–5 a The prolongation of R time indicates a decrease in clotting factor activity or the presence of anticoagulant substances. The K parameter indicates the levels of fibrinogen and platelets, the prolongation of which indicates a decrease in their levels. The size of ANGLE mainly indicates the level of fibrinogen. MA indicates the level of platelets and fibrinogen. The LY30 parameter indicates the level of fibrinolysis. The CI parameter indicates the comprehensive state of coagulation. Results of the thromboelastogram test a of the patient on the second day after scaling. The prolongation of R time indicates a decrease in clotting factor activity or the presence of anticoagulant substances. The K parameter indicates the levels of fibrinogen and platelets, the prolongation of which indicates a decrease in their levels. The size of ANGLE mainly indicates the level of fibrinogen. MA indicates the level of platelets and fibrinogen. The LY30 parameter indicates the level of fibrinolysis. The CI parameter indicates the comprehensive state of coagulation. TABLE 5Results of the VWD test of the patient on the fourth day after scaling.IndexDataReference rangevon Willebrand factor antigen (%)15.150–200von Willebrand factor antigen activity (%)3.350–200Ratio of VWF activity to VWF antigen0.22— Results of the VWD test of the patient on the fourth day after scaling. TABLE 6Laboratory tests of the patient on the fifth day after scaling.IndexDataReference rangeCoagulation factor VIII (%)27.015.0–60.0Maximum aggregation rate (6 μM ADP) (%)85.950.0–100.0ADP‐induced aggregation curveMonomial aggregationMonomial aggregationMaximum aggregation rate (0.3 g/L Arachidonic acid) (%)83.055.0–100.0Maximum aggregation rate (5 mg/L Collagen) (%)84.055.0–100.0Maximum aggregation rate (180 μM Epinephrine) (%)71.555.0–100.0 Laboratory tests of the patient on the fifth day after scaling. TABLE 7Laboratory tests of the son of the patient in the general hospital.IndexDataReference rangeProthrombin time (s)11.39.5–12.5Prothrombin activity (%)10080–130International normalized ratio1.040.85–1.15Fibrinogen (g/L)2.721.7–3.3Activated partial thromboplastin time (s)33.927.0–40.0Thrombin time (s)14.113.0–20.0D‐D dimer quantification (μg/mL FEU)2.35< 0.5Fibrinogen degradation products (μg/mL)7.3< 5.0Antithrombin (%)11680–120von Willebrand factor antigen (%)20.150–200von Willebrand factor antigen activity (%)2.150–200Ratio of VWF activity to VWF antigen0.10—Coagulation factor VIII (%)26.015.0–60.0 Laboratory tests of the son of the patient in the general hospital. Sixteen months later, following repeated counseling by the attending periodontist regarding the hereditary nature of VWD, the patient's father underwent hematological evaluation, with abnormal VWF antigen results shown in Table 8. TABLE 8Laboratory tests of the patient's father in the general hospital.IndexDataReference rangeProthrombin time (s)13.111–14.2International normalized ratio1.010.8–1.2Activated partial thromboplastin time (s)36.328–43.5Fibrinogen (g/L)3.022–4Thrombin time (s)16.414–21Antithrombin activity (%)11280–120Fibrinogen degradation products (μg/mL)2.230.1–5D‐D dimer quantification (μg/mL)0.490–0.5Coagulation factor VIII:C% (%)81.170–150von Willebrand factor antigen44.050–160 Laboratory tests of the patient's father in the general hospital. Conclusion and Results (Outcome and Follow‐Up) The final diagnosis of the patient was type 2M/2A VWD. The timeline of the case is shown in Figure 2. The periodontal specialist provided the patient with professional oral hygiene guidance, enabling her to master effective methods for self‐administered plaque control. Approximately 1 year later, she underwent supragingival ultrasonic scaling again, without any abnormal bleeding. One week later, she underwent subgingival ultrasonic scaling. There was bleeding after the surgery, but it was successfully controlled by local compression with an iodine‐phenol cotton ball. After the two procedures, there was no persistent abnormal gingival bleeding. Clinical timeline of the case. The timeline illustrates the sequence of key events from the initial dental scaling procedure to the final diagnosis of type 2M/2A von Willebrand disease (VWD). D0, day of scaling; D1, first day post‐scaling; D2, second day post‐scaling; D4, fourth day post‐scaling; D5, fifth day post‐scaling; VWF, von Willebrand factor. Discussion In the present case, the patient's bleeding history and laboratory findings—VWF: Ag level of 15.1% (< 30%) and VWF: Act/VWF: Ag ratio of 0.22 (< 0.7)—were consistent with type 2 VWD, an uncommon subtype [10]. Genetic testing identified a mutation in the A1 domain of the VWF gene—critical for VWF binding to platelet GP Ib—which most commonly causes type 2M VWD [15, 16]. The p.Arg1374Cys variant accounts for only 2.7% of all genetic variations in type 2 VWD and shares phenotypic features of both type 2M and 2A, leading to its recent classification as type 2M/2A VWD [17]. This case highlights two rare aspects: first, VWD is frequently underdiagnosed or misdiagnosed in non‐hematological settings; second, the identification of this uncommon genetic subtype via a routine dental procedure is exceptional. This underscores the critical role of dental interventions as sentinel events for detecting complex systemic disorders. Notably, among VWD diagnostic tests, most type 1 and 2 patients have normal or only slightly prolonged activated partial thromboplastin time (APTT), while only type 3 patients present with significantly prolonged APTT (correctable by normal plasma). Regardless of APTT status, VWF‐related testing is indicated for patients with a prominent bleeding or family history, such as the present patient with refractory gingival bleeding. In this case, APTT was within the reference range on the day of scaling and only 4.7 s above normal the following day—findings that are easily overlooked. Similarly, the patient's son had significant abnormalities in VWF‐related tests and factor VIII levels but normal APTT, and her father had low VWF antigen with normal APTT. These normal or mildly abnormal routine hematology results are the main cause of high misdiagnosis and missed diagnosis rates of VWD. Coagulation is a complex process influenced by multiple factors; thus, normal results of routine tests (complete blood count, platelet aggregation, bleeding/clotting time) do not guarantee normal coagulation function. Clinicians must understand the sensitivity, specificity, and clinical significance of each laboratory test to interpret results scientifically. Importantly, 60%–70% of patients with mild‐to‐moderate bleeding disorders have normal routine hemostasis test results [18, 19]. This challenge can be addressed by systematically collecting bleeding histories using validated tools, such as the International Society for Thrombosis and Hemostasis (ISTH) Bleeding Assessment Tool (BAT) [13]. As illustrated in Figure 3, clinical diagnosis and management should comprehensively integrate medical history, family history, clinical manifestations, and auxiliary test results—avoiding a rigid focus on a single aspect [13, 16]. The patient's ISTH‐BAT score was 9 points (abnormal: > 3 points in men, > 5 points in women), which prompted the periodontist to insist on hematology referral. Her VWD diagnosis was only established through integrated assessment of bleeding history, phenotypic laboratory findings, and genetic testing. This underscores a key clinical lesson for dental practitioners: when routine tests are inconclusive, structured bleeding history assessment (e.g., ISTH‐BAT) is paramount. The dentist's role in initiating this assessment—by recognizing disproportionate bleeding and systematically inquiring about past episodes and family history—is foundational to patient‐centered, interdisciplinary care. Diagnostic flowchart for von Willebrand disease (VWD). This flowchart outlines the stepwise diagnostic approach for VWD, incorporating personal and family bleeding history, laboratory screening tests (including complete blood count, activated partial thromboplastin time, and prothrombin time), VWF‐related assays (VWF antigen, VWF activity, and VWF activity/antigen ratio), and genetic testing. The final diagnosis of type 2M/2A VWD in this case is established through this integrated diagnostic pathway. VWF levels refer to VWF antigen (VWF:Ag) and/or platelet‐dependent VWF activity. Several recent studies have emphasized the underdiagnosis of mild bleeding disorders in the general population [20, 21]. For instance, recent evidence suggests that diagnostic delays in VWD can lead to preventable bleeding complications during minor surgical procedures, including oral surgery and dental extractions [22, 23], although there have been no similar reports so far related to periodontal scaling. This underscores the importance of preoperative bleeding risk assessment. ISTH‐BAT has been validated in multiple populations and shown to have high sensitivity for detecting type 1 and type 2 VWD [24]. Our case demonstrates its practical utility in a dental outpatient setting. Building on this evidence, the following discussion further illustrates how limited familiarity with VWD among non‐hematologists contributes to diagnostic delays. Unlike hemophilia, VWD is often unfamiliar to non‐hematology clinicians—likely the primary reason for the variable reported incidence rates. Due to limited awareness of VWD and other bleeding disorders, such bleeding manifestations are often attributed to local factors, delaying hematology referral and leading to VWD misdiagnosis. While VWD patients may experience abnormal bleeding after invasive dental procedures (e.g., tooth extraction and tonsillectomy) [22, 25, 26], abnormal bleeding following routine periodontal scaling leading to a congenital VWD diagnosis—as in this case—is extremely rare. The patient had a lifelong history of epistaxis, heavy menstrual bleeding, and significant cesarean section bleeding—all of which were previously attributed to local factors by other clinicians. Only after refractory post‐scaling bleeding did the periodontist strongly advise hematology referral, leading to VWD diagnosis. This underscores the importance of a holistic clinical perspective for dental practitioners—avoiding focus on isolated local organs and overlooking systemic factors that may contribute to local symptoms. For dental practitioners, this means viewing the oral cavity as an integral part of systemic health—bleeding gingiva can serve as a window to underlying hematological disorders. Clinicians often focus on superficial symptoms (e.g., bleeding, pain, and masses) and make cursory diagnoses, neglecting systemic factors and failing to fully evaluate the condition or refine treatment plans [27]. The human body is an integrated whole with interconnected tissues and organs; thus, effective clinical practice requires considering both local lesions and the patient's overall state—including interactions between local and systemic factors, structure and function, and mind and body. A comprehensive understanding of disease mechanisms is essential for accurate diagnosis and informed treatment decisions. This case exemplifies a common diagnostic pitfall: attributing bleeding to local causes (e.g., aggressive scaling, severe inflammation) without considering systemic predisposition. The patient's epistaxis and postoperative hemorrhage—retrospectively clear indicators—were previously overlooked, reinforcing the need for all clinicians, including dentists, to adopt a holistic diagnostic approach. Before periodontal scaling in patients suspected of having bleeding disorders, standardized questionnaires should be considered to assess personal and family bleeding histories—similar to preoperative assessment for invasive procedures [28]. Even with normal routine coagulation screening, patients (or family members) with recurrent unexplained epistaxis, gingival bleeding, hematomas, or abnormal menstrual bleeding should be evaluated for underlying conditions (e.g., mild hemophilia, VWD, factor XIII deficiency) to ensure procedural safety [29]. Patients with mild type 1 VWD can typically undergo periodontal examination and scaling safely without increased bleeding risk [30, 31]. In the present case, post‐scaling persistent bleeding was multifactorial, involving gingival inflammation, scaling depth, and the specific VWD subtype. One year later, repeat scaling was performed without persistent bleeding, attributed to two key measures: effective oral hygiene management (to minimize inflammation) and meticulous periodontal technique (to avoid excessive tissue trauma). This case emphasizes that even minimally invasive dental procedures can precipitate complications in patients with undiagnosed bleeding disorders, reinforcing the importance of thorough preprocedural screening and tailored, conservative dental management. For VWD patients with severe gingival bleeding unresponsive to 20–30 min of pressure or ice application, antifibrinolytic drugs can be administered locally or systemically: ① Tranexamic acid: 25 mg/kg orally three times daily or 15 mg/kg intravenously every 8 h; ② Aminocaproic acid: 4–5 g intravenously (initial dose), followed by 1 g/h until bleeding is controlled (maximum 24 g/day). Antifibrinolytics carry a thrombosis risk and should be avoided in patients with hematuria. Local application of thrombin or fibrin glue can also aid in managing oral mucosal bleeding [13]. Additionally, safe suturing techniques are vital for local hemostasis after invasive dental procedures. After controlling gingival bleeding, dentists must refer patients to a hematologist for specialized VWD management. While the local hemostatic protocol described here is important, the dentist's decision to refer—based on clinical suspicion rather than conclusive test results—was the pivotal intervention. This case underscores the critical role of dentists as frontline clinicians in identifying systemic disorders. It demonstrates that a routine dental procedure can serve as the pivotal event leading to the diagnosis of a congenital bleeding disorder such as VWD in adulthood. Key takeaways for clinical practitioners include the importance of vigilance for disproportionate bleeding, thorough assessment of systemic and family histories, and awareness of bleeding disorders. Dentists and other frontline clinicians must integrate this holistic perspective—looking beyond local pathology—into daily practice. By doing so, they can act as “first responders,” reducing diagnostic delay and enhancing patient‐centered care, and transforming routine oral examinations into vital opportunities for early systemic disease detection. Author Contributions Shuhuan Shang: conceptualization, investigation, writing – original draft, writing – review and editing, methodology, project administration, supervision. Zhengguo Cao: conceptualization, investigation, methodology. Huihui Zhang: conceptualization, investigation, writing – original draft, methodology. Nan Qiu: conceptualization, investigation, writing – review and editing, methodology. Funding The authors have nothing to report. Ethics Statement This case report is a retrospective review of medical records and was exempt from ethical approval by the Institutional Review Board of the Hospital of Stomatology, Wuhan University. This case report was conducted in accordance with the Declaration of Helsinki. Consent Written informed consent was obtained from the patient for the publication of this case report, including all clinical details, laboratory results, and any relevant images; this ascertained the patient's permission for her clinical information and photographic material to be published and confirmed her understanding that her clinical information would be published on an open access basis and may be freely accessed throughout the world. A copy of the consent form is available for review by the Editor of this journal. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors wish to thank Dai Jing of Ruijing Hospital Affiliated with the School of Medicine, Shanghai Jiaotong University, for guiding on laboratory diagnosis of VWD, and Hao Changpeng of Harbin Institute of Hematology and Cancer for guiding on Hematology. The authors would like to thank Zhu Guangxun of Tongji Hospital Affiliated with Huazhong University of Science and Technology for his assistance in data collection. We also thank the patient for agreeing to participate and for providing consent for publication. Data Availability Statement All data generated or analyzed during this study are included in this published article. The original medical records and imaging data are stored at the Hospital of Stomatology, Wuhan University, and are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in this published article. The original medical records and imaging data are stored at the Hospital of Stomatology, Wuhan University, and are available from the corresponding author upon reasonable request.